CA-19-9

Revision as of 23:29, 17 January 2009 by C Michael Gibson (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
CA-19-9

WikiDoc Resources for CA-19-9

Articles

Most recent articles on CA-19-9

Most cited articles on CA-19-9

Review articles on CA-19-9

Articles on CA-19-9 in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on CA-19-9

Images of CA-19-9

Photos of CA-19-9

Podcasts & MP3s on CA-19-9

Videos on CA-19-9

Evidence Based Medicine

Cochrane Collaboration on CA-19-9

Bandolier on CA-19-9

TRIP on CA-19-9

Clinical Trials

Ongoing Trials on CA-19-9 at Clinical Trials.gov

Trial results on CA-19-9

Clinical Trials on CA-19-9 at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on CA-19-9

NICE Guidance on CA-19-9

NHS PRODIGY Guidance

FDA on CA-19-9

CDC on CA-19-9

Books

Books on CA-19-9

News

CA-19-9 in the news

Be alerted to news on CA-19-9

News trends on CA-19-9

Commentary

Blogs on CA-19-9

Definitions

Definitions of CA-19-9

Patient Resources / Community

Patient resources on CA-19-9

Discussion groups on CA-19-9

Patient Handouts on CA-19-9

Directions to Hospitals Treating CA-19-9

Risk calculators and risk factors for CA-19-9

Healthcare Provider Resources

Symptoms of CA-19-9

Causes & Risk Factors for CA-19-9

Diagnostic studies for CA-19-9

Treatment of CA-19-9

Continuing Medical Education (CME)

CME Programs on CA-19-9

International

CA-19-9 en Espanol

CA-19-9 en Francais

Business

CA-19-9 in the Marketplace

Patents on CA-19-9

Experimental / Informatics

List of terms related to CA-19-9

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

CA-19-9 is a tumor marker.

Interpretation

CA 19-9 is elevated in most patients with advanced pancreatic cancer, but it may also be elevated in other cancers, conditions, and diseases such as colorectal cancer, lung cancer, gallbladder cancer, gallstones, pancreatitis, cystic fibrosis, and liver disease.

Other causes of bile duct obstruction may also cause very high CA 19-9 levels, which fall when the blockage is cleared.

If the bile ducts are blocked, wait a week or two after the blockage is removed or treated to check CA 19-9 levels.

Differential Diagnosis

In alphabetical order. [1] [2]

Increased level of CA-19-9

Malignant Diseases

Non-Malignant Diseases

References

  1. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:77 ISBN 1591032016
  2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:68 ISBN 140510368X

Acknowledgements

The content on this page was first contributed by Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]

Template:SIB


Template:WikiDoc Sources